Latest News | Theragnostic Imaging

The RNTreg OUS registry had its official opening on June 23, 2025.

Jun 23, 2025 1 min read

Paper on the Phase 0-trial of AB001 accepted for publication

Our research group is pleased to announce that we have had results from a phase 0-trial on AB001, a novel PSMA-targeted radioligand labeled with the α-emitter 212Pb, accepted for publication in the Journal of Nuclear Medicine. The study explores the use of γ-camera imaging to assess biodistribution and uptake of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC).

The study was conducted at Oslo University Hospital, and sponsored by ARTBIO. The publication was a result of an excellent multidisiplinary collaboration, and especially the joint first authors Kjetil Berner (Department of Oncology) and Eivor Hernes (Department of Nuclear Medicine), together with Monika Kvassheim and senior author Caroline Stokke (our group) played key roles. Group members Simen Rykkje Grønningsæter and Lars Tore Gyland Mikalsen also gave valuable contributions. The work showed that AB001 can be safely administered and imaged at a microdose of only 10 MBq, and successfully demonstrated metastatic targeting. The findings offer valuable insights into the biodistribution and clearance of 212Pb-labeled radioligands, paving the way for further clinical development in targeted alpha therapy.

Link to the (Open Acces) publication ahead of print

Mar 21, 2025 1 min read

Paper on the Phase 0-trial of AB001 accepted for publication

Position Open for a Medical Physicist at Oslo University Hospital

The Section for Nuclear Medicine Physics at Oslo University Hospital (OUS) is offering a full-time temporary position for a medical physicist.

Jan 28, 2025 1 min read

Research Grant Awarded to Advance Alpha Therapy Imaging

The Theragnostic Imaging group has received funding for a three-year full time research position + running costs from the Southern and Eastern Norway Regional Health Authority for ImALPHA!

Dec 22, 2024 1 min read

Research Grant Awarded to Advance Alpha Therapy Imaging

Presentation at 6th Targeted Radiopharmaceutical Summit Europe

Caroline Stokke delivered an invited plenary presentation on “Dosimetry for first-in-human studies and early phase clinical trials” at the 6th Targeted Radiopharmaceutical Summit Europe.

Last updated on Dec 6, 2024 1 min read

Presentation at 6th Targeted Radiopharmaceutical Summit Europe

EANM 2024 - Hamburg

Our group attended EANM 2024, which was held in Hamburg, Germany.

Oct 4, 2024 1 min read

Congratulations Mia and Johan!

Mia Frivik and Johan Høiness have defended their master’s theses. Johan was supervised by Monika Kvassheim, Caroline Stokke, and Eivor Hernes, while Mia was supervised by Monika Kvassheim, Caroline Stokke, and Andreas Tulipan.

Jun 20, 2024 1 min read

Caroline becomes chair of the EANM Dosimetry Commitee

Caroline Stokke has been appointed Chair of the Dosimetry Committee within the European Association of Nuclear Medicine (EANM) after serving as a committee member for five years. In her role as Chair, she works to promote dosimetry practices, develop guidelines, and support education and training initiatives, all aimed at optimizing the use of radiopharmaceuticals in nuclear medicine. Her first term spans three years (2024–2026), with the possibility of a second three-year term.

Feb 10, 2024 1 min read

Caroline becomes chair of the EANM Dosimetry Commitee

The year of 2023 for "Theragnostic Imaging"

The year 2023 has been an active and productive one for our research group, reflecting the collective efforts of our members and collaborators. We are pleased to report 17 publications in peer-reviewed journals, covering topics ranging from dosimetry in molecular radiotherapy to imaging optimization and clinical applications. These publications reflect the broad scope of our work and our commitment to advancing nuclear medicine physics.

Our team also had a strong presence at international conferences, delivering 14 presentations at international meetings such as EANM 2023, SNMMI 2023, and BiGART 2023. These included both invited talks and research presentations, addressing topics like theragnostic dosimetry, radiomic analysis, and clinical trial results. Members of our group also contributed to conference organization, serving on abstract committees and chairing multiple sessions.

This year also brought opportunities for mentorship and recognition. We supported early-career researchers through involvement in PhD defenses and master’s thesis evaluations. Notably, our group received the Clinical Paper of the Year award from Molecular Imaging and Biology, acknowledging our contributions to advancing imaging and treatment strategies in non-Hodgkin lymphoma. As the year ends, we look forward to continuing our collaborative efforts to improve diagnostic and therapeutic approaches in nuclear medicine.

Jan 1, 2024 1 min read

Caroline joins the executive board of EURAMED

Caroline has joined the Board of Executives of EURAMED, the European Alliance for Medical Radiation Protection Research. She will serve as the EANM representative on the board. In this capacity, she contributes to efforts to improve medical care through sustainable research in radiation protection, foster collaboration among researchers and clinicians, and support harmonized strategies for advancing European research initiatives in radiation protection.

Caroline has joined the Board of Executives of EURAMED, the European Alliance for Medical Radiation Protection Research. She will serve as the EANM representative on the board. In this role, she contributes to efforts aimed at improving medical care through sustainable research in radiation protection, fostering collaboration among researchers and clinicians, and supporting harmonized strategies for advancing European research initiatives in radiation protection.

Link to the EURAMED announcement

Oct 10, 2023 1 min read